Coherus BioSciences (NASDAQ:CHRS – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership. Valuation & Earnings This table compares Coherus BioSciences and AVROBIO’s […]
Analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) to report ($0.98) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Coherus BioSciences’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($1.13). Coherus BioSciences reported earnings per share of ($0.40) in the same quarter […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating […]
Equities analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) to post $56.08 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Coherus BioSciences’ earnings, with the lowest sales estimate coming in at $54.97 million and the highest estimate coming in at $57.19 million. Coherus BioSciences posted sales […]
Zacks Investment Research lowered shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical […]